High-value life science acquisitions seldom occur without scrutiny. As governments increasingly treat advanced biotechnology, pharmaceutical manufacturing capabilities and proprietary research platforms as strategically sensitive assets, cross-border transactions in the sector are more likely than ever to trigger foreign investment screening and national security review. At the same time, the core patent portfolios, platform technologies and regulatory data packages driving these deals often attract immediate attention from competitors seeking to challenge the strength and scope of acquired IP before commercial launch.
This session will examine how legal teams safeguard the value of life science acquisitions by navigating foreign investment clearance processes while proactively managing the IP risks associated with newly acquired technologies. Bringing together corporate and IP perspectives, the discussion will explore how your company can structure transactions and prepare for potential IP challenges that may arise once high-profile acquisitions become public.
- When do life science acquisitions trigger foreign investment screening, and how can companies manage the resulting deal approval risk?
- How do regulators assess transactions involving strategically important life science technologies and IP portfolios?
- How can legal teams identify vulnerabilities in acquired patent portfolios and assess FTO risks before completing a transaction?
- What early IP and legal measures need to be put in place to protect newly acquired products?
- How should legal teams coordinate post acquisition to safeguard exclusivity and maximise the long-term value of acquired assets?